Clinical Trial

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA

Study acronym: BEXAR
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy. The main purpose of the Study is to analyze the safety (to find out how safe or toxic a treatment is to appropriately manage the risks) and efficacy (to find out how effective a treatment is) of bexmarilimab combined with doxorubicin in participants who have STS.
Trial Details
NCT Number NCT07460986
Lead Sponsor MedSIR
Collaborators: Faron Pharmaceuticals Ltd
Conditions Sarcoma of Soft Tissue
Enrollment 278 participants
Start Date 2026-07
Primary Completion 2028-07 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-10